Online Inquiry
Oncolytic Viral Therapy Development for Prostate Cancer
Oncolytic viral therapy is a form of immunotherapy that uses viruses to infect and destroy cancer cells. Alfa Cytology is committed to providing a comprehensive one-stop Oncolytic viral therapy development service tailored to our clients' requirements against prostate cancer.
Introduction to Oncolytic Viral Therapy
Oncolytic virotherapy is an emerging novel tumor therapeutic approach that selectively replicates in and destroys tumor cells while leaving normal cells undamaged. As we approach the year 2000, it is technically feasible to genetically engineer a series of modifications to wild-type viruses. The modified oncolytic virus could incorporate desired exogenous genes that could exert far-reaching antitumor effects through different mechanisms.
Fig. 1 The OVs can specifically
lyse tumor cells, sparing normal cells. (Wang, G., et al. 2022)
Classification of Oncolytic Viral Therapy
Oncolytic viruses are derived from single- or double-stranded DNA or RNA viruses according to their nucleic acid type. Except for reovirus (dsRNA) and parvovirus (ssDNA). dsDNA viruses mainly include adenovirus, vaccinia virus, and herpesvirus. ssRNA viruses are composed of two main categories: positive-sense and negative-sense.
Advantages of Oncolytic Viral Therapy
Precise targeting of cancer cells
Oncolytic viruses reduce the regulation of antiviral pathways in tumor cells by interacting with specific cellular receptors, or by exploiting defects in tumor suppressor genes, or by designing viral vectors with specific knockout genes to precisely break down cancer cells.
Broad activation of immune responses
With regard to the activation of tumor immunity, oncolytic viruses appear to be superior to ICIs and other targeted drugs, because ICIs specifically target immune checkpoints, while small molecule drugs only target specific molecules.
Multi-mechanism integrated anti-cancer
In the context of oncolytic viruses, a wide range of anti-tumor immune activities will be induced to fight against tumors. In contrast to the limited effectiveness of other therapies, oncolytic viruses can systematically and comprehensively kill tumors in multiple ways.
Oncolytic Viral Therapy Development for Prostate Cancer
Today, in prostate cancer therapy, research on oncolytic viral therapy is actively progressing. To date, several oncolytic viral drugs have been approved globally, which indicates that oncolytic viral therapies have great promise for clinical use.
| Name | Phase | Company | Country |
| CAN-2409 | Phase III | Candel Therapeutics | USA |
| AdV-Tk | Phase III | Advantagene | USA |
| Delytact | Market Approval | Daiichi Sankyo Company | Japan |
Our Services
ssRNA and dsDNA viruses are the most prevalent in oncolytic viral products, except for reovirus (dsRNA) and parvovirus (ssDNA). Alfa Cytology has been deeply involved in the field of oncolytic viral therapy development for many years, and we have professional knowledge, extensive experience, and cutting-edge technology to escort you through the process of lysosomal viral therapy development.
Herpesvirus
Adenovirus
Vaccinia virus
Reovirus
Coxsackievirus
Seneca Valley virus
Poliovirus
Measles virus
Newcastle disease virus
Vesicular stomatitis virus
Workflow of Oncolytic Viral Therapy Development
Oncolytic Virus Construction
Our company thoroughly studied the properties of various viruses, taking into account their exploitability, tendency, potential function, and application, and established a specific oncolytic virus construction process for different types of viruses.
Oncolytic Virus Engineering
Our company has developed a variety of engineering methods that take full advantage of the natural properties of various viruses. With a rich background in immunotherapy development, we optimize oncolytic viruses to enhance tumor targeting, tumor lysis and the effectiveness of initiating anti-cancer immunity.
Oncolytic Virus Characterization
To ensure the comprehensiveness of the research, our company designs in vitro and in vivo preclinical validation studies for each oncolytic virus according to the targeted disease nature, virus characteristics, mechanism of action, etc.
Our Advantages
We are committed to providing efficient, innovative and reliable development solutions by leveraging our in-depth professional knowledge, adopting cutting-edge technologies, and enforcing strict quality control standards.
Professional Knowledge
Cutting-Edge Technologies
Quality Control
With advances in genetic engineering technology, oncolytic viral therapy has been adopted as a versatile platform for the development of novel anti-tumor strategies, alone or in combination with other therapies. Our mission is to advance prostate cancer therapy by providing one-stop oncolytic viral therapy development services. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.
Reference
- Wang, G., et al. Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter. International journal of molecular sciences. 2022, 23(20): 12647.
For research use only.